Breaking News Instant updates and real-time market news.

MYL

Mylan

$41.65

-0.2 (-0.48%)

07:38
06/14/18
06/14
07:38
06/14/18
07:38

Morgan Stanley says generic Advair delay a small negative for Mylan

Morgan Stanley analyst David Risinger called Mylan's announcement that generic Advair will not be approved by its June 27 action date a "small negative, but not a major surprise." He sees potential for approval this fall, while noting that the company previously warned with its Q1 earnings release that there was risk that it could need to lower its 2018 guidance range. He keeps an Overweight rating on Mylan shares, citing the stock's low valuation and the company's pipeline opportunities.

  • 13

    Nov

MYL Mylan
$41.65

-0.2 (-0.48%)

06/05/18
MSCO
06/05/18
NO CHANGE
Target $50
MSCO
Overweight
Neulasta biosimilar could 'reignite' Mylan momentum, says Morgan Stanley
Morgan Stanley analyst David Risinger said FDA approval of Fulphila, Mylan's (MYL) biosimilar to Amgen's (AMGN) Neulasta, should be a "substantial and durable" profit opportunity and could "reignite" Mylan's upward momentum. He notes that Mylan anticipates launching Fulphila in the coming weeks and that the FDA biosimilar user fee act action date for Coherus' (CHRS) Neulasta biosimilar is November 3. Risinger has an Overweight rating and $50 price target on Mylan shares.
06/13/18
BMOC
06/13/18
NO CHANGE
Target $50
BMOC
Outperform
Mylan to have only a 'minor' delay to generic Advair approval, says BMO Capital
BMO Capital analyst Gary Nachman kept his Outperform rating and $50 price target on Mylan after today's post-market close disclosure by the FDA that the company's generic Advair had minor deficiencies. The analyst says that while this is not an "ideal scenario for this much-anticipated catalyst", he confirmed with the management that the FDA used the term "minor" in its letter. Nachman maintains that Mylan is still "very close" to generic Advair, adding that "there will only be a relatively minor delay to ultimate approval".
06/14/18
MZHO
06/14/18
NO CHANGE
Target $51
MZHO
Buy
Mylan to recover from 'modest' generic Advair delay, says Mizuho
Mizuho analyst Irina Koffler says Mylan's "modest" delay for generic Advair approval is unsurprising and unlikely to impact the company's 2018 guidance. She expects the stock to recover and reiterates a Buy rating on the name with a $51 price target.
06/14/18
RBCM
06/14/18
NO CHANGE
Target $42
RBCM
Sector Perform
Mylan's stock may pull back through Q2, says RBC Capital
RBC Capital analyst Randall Stanicky kept his $42 price target and Sector Perform rating on Mylan following yesterday's FDA delay of generic Advair due to "minor deficiencies". The analyst notes that the company may be faced with worse than expressed business pressure and is also concerned that the Street may have over-modeled the Advair contribution, warning that the stock price may pull back through Q2. Stanicky says investors should await a better entry point opportunity on Mylan.

TODAY'S FREE FLY STORIES

AMRN

Amarin

$10.00

7 (233.33%)

10:00
09/24/18
09/24
10:00
09/24/18
10:00
Options
Active trading in Amarin as shares surge »

Active trading in Amarin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 01

    Oct

KORS

Michael Kors

$68.56

-4.11 (-5.66%)

10:00
09/24/18
09/24
10:00
09/24/18
10:00
Hot Stocks
Michael Kors falls -5.7% »

Michael Kors is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DWT

Britannia Bulk

$5.55

-0.32 (-5.45%)

10:00
09/24/18
09/24
10:00
09/24/18
10:00
Hot Stocks
Britannia Bulk falls -5.7% »

Britannia Bulk is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PPDF

PPDAI Group

$6.07

-0.53 (-8.03%)

10:00
09/24/18
09/24
10:00
09/24/18
10:00
Hot Stocks
PPDAI Group falls -8.0% »

PPDAI Group is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SA

Seabridge Gold

$12.80

1.55 (13.78%)

10:00
09/24/18
09/24
10:00
09/24/18
10:00
Hot Stocks
Seabridge Gold rises 12.9% »

Seabridge Gold is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

CRC

California Resources

$44.89

5.36 (13.56%)

10:00
09/24/18
09/24
10:00
09/24/18
10:00
Hot Stocks
California Resources rises 13.5% »

California Resources is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

XON

Intrexon

$17.02

2.525 (17.42%)

10:00
09/24/18
09/24
10:00
09/24/18
10:00
Hot Stocks
Intrexon rises 17.5% »

Intrexon is up 17.5%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:57
09/24/18
09/24
09:57
09/24/18
09:57
General news
Market starts lower as new tariffs ratchet up China tensions »

Stock futures were weak…

C

Citi

$74.33

0.2 (0.27%)

09:55
09/24/18
09/24
09:55
09/24/18
09:55
Options
Citi put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 28

    Sep

  • 21

    Oct

  • 14

    Jan

  • 15

    Apr

  • 13

    Jul

  • 12

    Oct

EW

Edwards Lifesciences

$161.52

7.81 (5.08%)

, ALXN

Alexion

$128.15

6.18 (5.07%)

09:55
09/24/18
09/24
09:55
09/24/18
09:55
Options
Early notable gainers among liquid option names on September 24th »

Notable gainers among…

EW

Edwards Lifesciences

$161.52

7.81 (5.08%)

ALXN

Alexion

$128.15

6.18 (5.07%)

APA

Apache

$47.61

1.665 (3.62%)

ABT

Abbott

$71.27

2.22 (3.22%)

NFX

Newfield Exploration

$29.85

0.81 (2.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 24

    Sep

  • 24

    Sep

  • 17

    Oct

  • 18

    Feb

09:55
09/24/18
09/24
09:55
09/24/18
09:55
Conference/Events
UBS consumer goods analyst to hold an analyst/industry conference call »

Consumer Goods Analyst…

SBAC

SBA Communications

$159.90

-0.62 (-0.39%)

09:54
09/24/18
09/24
09:54
09/24/18
09:54
Conference/Events
SBA Communications management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

09:50
09/24/18
09/24
09:50
09/24/18
09:50
General news
Florence Fallout: »

Florence Fallout:…

09:49
09/24/18
09/24
09:49
09/24/18
09:49
Conference/Events
RBC Capital equity strategy analyst to hold an analyst/industry conference call »

U.S. Equity Strategy…

RHHBY

Roche

$0.00

(0.00%)

09:49
09/24/18
09/24
09:49
09/24/18
09:49
Hot Stocks
Genentech: Tecentriq + chemotherapy reduced risk of disease worsening in trial »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 03

    Oct

UNFI

United Natural Foods

$30.73

-0.29 (-0.93%)

09:47
09/24/18
09/24
09:47
09/24/18
09:47
Recommendations
United Natural Foods analyst commentary  »

United Natural Foods…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

YEXT

Yext

$23.24

-1.53 (-6.18%)

09:47
09/24/18
09/24
09:47
09/24/18
09:47
Hot Stocks
Yext falls -5.4% »

Yext is down -5.4%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

09:47
09/24/18
09/24
09:47
09/24/18
09:47
Hot Stocks
Genentech's Entrectinib showed durable response rate of over 2 years in NSCLC »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 03

    Oct

DWT

Britannia Bulk

$5.57

-0.3 (-5.11%)

09:47
09/24/18
09/24
09:47
09/24/18
09:47
Hot Stocks
Britannia Bulk falls -5.3% »

Britannia Bulk is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PPDF

PPDAI Group

$6.01

-0.59 (-8.94%)

09:47
09/24/18
09/24
09:47
09/24/18
09:47
Hot Stocks
PPDAI Group falls -9.5% »

PPDAI Group is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

P

Pandora

$9.65

0.57 (6.28%)

09:47
09/24/18
09/24
09:47
09/24/18
09:47
Hot Stocks
Pandora rises 6.2% »

Pandora is up 6.2%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XON

Intrexon

$16.14

1.645 (11.35%)

09:47
09/24/18
09/24
09:47
09/24/18
09:47
Hot Stocks
Intrexon rises 12.1% »

Intrexon is up 12.1%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SA

Seabridge Gold

$12.45

1.2 (10.67%)

09:47
09/24/18
09/24
09:47
09/24/18
09:47
Hot Stocks
Seabridge Gold rises 10.6% »

Seabridge Gold is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

HKMPY

Hikma

$0.00

(0.00%)

09:45
09/24/18
09/24
09:45
09/24/18
09:45
Conference/Events
Hikma has a conference call hosted by JPMorgan »

JPMorgan Analyst Gordon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

09:43
09/24/18
09/24
09:43
09/24/18
09:43
Conference/Events
The National Press Club to host a luncheon meeting »

Craig Newmark, founder of…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.